Case Studies

Rare Disease Experience

With over 20 years of experience in the Canadian rare disease landscape, CLSG has successfully built biotech startups and launched multiple therapies in areas such as:

Enzyme replacement therapies for Type 1 Gaucher disease, Fabry disease, and Pompe disease
Multiple Sclerosis
Hemophilia A and B
Rare Blood Disorders (aTTP)
Spinal Muscular Atrophy
NTRK gene fusion cancers
Amyotrophic Lateral Sclerosis (ALS)

Recent Consulting Engagements

CLSG has recently completed major projects including:

Monoclonal Antibody Launch for Infectious Disease: Conducted a full Canadian landscape analysis and led engagement with Health Canada, public health agencies, patient advocacy groups, and manufacturing partners.
Motor Neuron Disease Company Launch: Developed the full Canadian launch plan, engaged with key opinion leaders, advocacy groups, and regulatory agencies.
Rare Neurological Disease Therapy Launch: Conducted market analysis, business case development, and resource planning.
pCPA Negotiations for Epilepsy Therapies: Provided analytics and negotiation support for two major therapy approvals.
In-Licensing Support for Rare Oncology, Cardiology, Neuropathy, and Gastroenterology: Delivered market analysis, pricing determinations, and licensing negotiations for multiple biotech companies.